Updates are available Correction dated 2023-07-03
Click to view Correction: https://doi.org/10.1007/s12282-023-01479-w
-
Authors
Saeki, Sumito https://orcid.org/0009-0001-8225-923X
Iwatani, Tsuguo https://orcid.org/0000-0001-7162-1515
Kitano, Atsuko https://orcid.org/0000-0001-8881-3329
Sakurai, Naomi
Tanabe, Yuko
Yamauchi, Chikako https://orcid.org/0000-0003-1799-8535
Igarashi, Ataru https://orcid.org/0000-0001-6307-6916
Kajimoto, Yusuke https://orcid.org/0000-0003-3681-5757
Kuba, Sayaka https://orcid.org/0000-0002-0225-099X
Hara, Fumikata https://orcid.org/0000-0001-8025-3494
Sagara, Yasuaki https://orcid.org/0000-0001-5705-1739
Ohno, Shinji https://orcid.org/0000-0003-2093-3353
,
-
Funding
Funding for this research was provided by:
Japanese Breast Cancer Society (25)
- License Information
-
More Information
Article History
Received: 20 April 2023
Accepted: 5 June 2023
First Online: 13 June 2023
Change Date: 3 July 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s12282-023-01479-w
Declarations
:
: AI reports consultancy fees, grants, and other payments from multiple companies, including Pfizer Japan Inc., Terumo Corporation, Becton Dickinson and Company, Milliman Inc., Taiho Pharmaceutical Co. Ltd., Abbvie GK, Ayumi Pharmaceutical Inc., Chugai Pharmaceuticals Inc., Eisai Inc., GSK, Nippon Boehringer Ingelheim Inc., Novartis Pharma K.K., Novo Nordisk Japan Inc., Ono Pharmaceutical Inc., Sumitomo Dainippon Pharma Inc., Takeda Pharmaceutical Inc., Otsuka Pharmaceutical Co., Ltd., Sanofi Japan Inc., Gilead Sciences K.K., Boston Scientific Japan Inc., Intuitive Surgical GK, Astellas Pharma Inc., CSL Behring Japan Inc., Fuji Film Inc., and Medilead Inc. YK is an employee of MSD K.K. FH has received payments or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Kyowa Kirin, Pfizer, Eli Lilly, Chugai, and Eisai. The other authors declare that they have no conflict of interest.
: Participants provided informed consent on the application before the survey. The protocol was approved by the Institutional Ethics Committee of the Cancer Institute Hospital of the Japan Cancer Institute, the lead investigator of the group study (No. 2020–1151), and the collaborating institutions followed suit.
